New publication – Science Translational Medicine

“The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance” Dr Gilles Courtemanche, BIOASTER Antimicrobials Program Head is co-author of a scientific publication...

BIOASTER publishes a new article in Frontiers in Immunology .

BIOASTER in collaboration with Cochin Hospital and the REALISM project consortium (study of the pathophysiology of intensive care patients and on biomarkers), has just published the article entitled “Assessing the...

DxPX Conference support to the Virtual US event in July

BIOASTER is proud to support DxPx Conference Industry & Investor Conference, the unique international partnering conference with focus on #diagnostics, #PrecisionMedicine & research tools. During the virtual US event from July 27th – 31st, 2021, Xavier Morge,...

KALEIDO & BIOASTER: a successful completion

Kaleido Biosciences and BIOASTER are glad to announce the successful completion of a collaborative project that provided new insights into ways Kaleido’s Microbiome Metabolic Therapies (MMT™) modulate the integrity and function of...

New collaboration with PiLeJe Laboratoire

PiLeJe Laboratoire to collaborate with BIOASTER to investigate the health potential of a probiotic selection Pileje Laboratoire, a French company leader in probiotic-based dietary supplements in Europe and specialized in...

Antimicrobials Program Highlights 2020

Hopefully, we will have a chance to share updates face to face, in the meantime we are happy to highlight some of the 2020 Antimicrobials Program achievements. If this should...

LUMI-Seq®: New video on line!

LUMI-Seq®: New video on line! Check out the new Designed BY BIOASTER video about LUMI-Seq® technology: A novel targeted sequencing  technology for generating long reads from Illumina sequencers.